Trial · NCT03397706
Results by group111
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 111
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number (Proportion) of Participants With Adverse Events (AEs) | Phase 1b Dose Escalation Cohort 1 | 7 | Participants | ||
| Number (Proportion) of Participants With Adverse Events (AEs) | Phase 1b Dose Escalation Cohort 2a | 5 | Participants | ||
| Number (Proportion) of Participants With Adverse Events (AEs) | Phase 1b Dose Escalation Cohort 2b | 4 | Participants | ||
| Number (Proportion) of Participants With Adverse Events (AEs) | Phase 1b Dose Escalation Cohort 2c | 4 | Participants | ||
| Number (Proportion) of Participants With Adverse Events (AEs) | Phase 1b Dose Escalation Cohort 3 | 5 | Participants | ||
| Number (Proportion) of Participants With Adverse Events (AEs) | Phase 2 Dose Expansion - Capsule | 30 | Participants | ||
| Number (Proportion) of Participants With Adverse Events (AEs) | Phase 2 Dose Expansion - Tablet | 9 | Participants | ||
| Number (Proportion) of Participants With Dose-Limiting Toxicities (DLTs) in Phase 1b | Phase 1b Dose Escalation Cohort 1 | 4 | Participants | ||
| Number (Proportion) of Participants With Dose-Limiting Toxicities (DLTs) in Phase 1b | Phase 1b Dose Escalation Cohort 2a | 0 | Participants | ||
| Number (Proportion) of Participants With Dose-Limiting Toxicities (DLTs) in Phase 1b | Phase 1b Dose Escalation Cohort 2b | 0 | Participants | ||
| Number (Proportion) of Participants With Dose-Limiting Toxicities (DLTs) in Phase 1b | Phase 1b Dose Escalation Cohort 2c | 0 | Participants | ||
| Number (Proportion) of Participants With Dose-Limiting Toxicities (DLTs) in Phase 1b | Phase 1b Dose Escalation Cohort 3 (RP2D) | 0 | Participants | ||
| Overall Response Rate | Phase 1b Dose Escalation Cohort 1 | Complete Response | 2 | Participants | |
| Overall Response Rate | Phase 1b Dose Escalation Cohort 2a | Complete Response | 1 | Participants | |
| Overall Response Rate | Phase 1b Dose Escalation Cohort 2b | Complete Response | 0 | Participants | |
| Overall Response Rate | Phase 1b Dose Escalation Cohort 2c | Complete Response | 0 | Participants | |
| Overall Response Rate | Phase 1b Dose Escalation Cohort 3 | Complete Response | 1 | Participants | |
| Overall Response Rate | Phase 2 Dose Expansion - Capsule | Complete Response | 3 | Participants | |
| Overall Response Rate | Phase 2 Dose Expansion - Tablet | Complete Response | 1 | Participants | |
| Overall Response Rate | Phase 1b Dose Escalation Cohort 1 | Partial Response | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03397706/results